Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.
Epistemonikos ID: 374683640f35d8ef95470a9765bf9a87bc227207
First added on: May 17, 2024